Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine
- PMID: 6590568
- PMCID: PMC425236
- DOI: 10.1172/JCI111498
Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine
Abstract
We have previously demonstrated that continuous exposure of human HL-60 human promyelocytes to 1-beta-D-arabinofuranosylcytosine (ara-C) results in the induction of terminal differentiation to monocyte-like cells. The present study extends these findings by demonstrating that ara-C induces hemoglobin synthesis in human K562 erythroleukemia cells. This effect occurs maximally at an ara-C concentration (5 X 10(-7) M) that results in K562 cytostasis. In contrast to the reversible effects of hemin and hydroxyurea on globin synthesis in this cell line, we have found that the induction of K562 hemoglobin synthesis by ara-C is irreversible. An induction of K562 hemoglobin synthesis also occurs with aphidicolin, another inhibitor of S-phase DNA synthesis, but not with vinblastine, an inhibitor of mitosis. Finally, ara-C induction of a differentiated K562 phenotype is accompanied by the loss of self-renewal capacity, a finding consistent with terminal differentiation.
Similar articles
-
Effects of 1-beta-D-arabinofuranosylcytosine and phorbol ester on differentiation of human K562 erythroleukemia cells.Mol Pharmacol. 1985 Jun;27(6):683-8. Mol Pharmacol. 1985. PMID: 3858662
-
Hemoglobin induction by Ara-C in human erythroleukemic cells (K562) is cell-cycle dependent.Leuk Res. 1989;13(8):683-8. doi: 10.1016/0145-2126(89)90057-x. Leuk Res. 1989. PMID: 2796376
-
Altered queuine modification of transfer RNA involved in the differentiation of human K562 erythroleukemia cells in the presence of distinct differentiation inducers.Cancer Res. 1994 Apr 15;54(8):2192-8. Cancer Res. 1994. PMID: 7513611
-
Enhancement by hemin of the sensitivity of K562 human leukemic cells to 1-beta-D-arabinofuranosylcytosine.Cancer Res. 1986 Mar;46(3):1239-43. Cancer Res. 1986. PMID: 3455882
-
Cellular and clinical pharmacology of low-dose ara-C.Semin Oncol. 1985 Jun;12(2 Suppl 3):200-7. Semin Oncol. 1985. PMID: 3925558 Review.
Cited by
-
The DNA methylation system in proliferating and differentiated cells.Cell Biophys. 1989 Aug-Oct;15(1-2):79-86. doi: 10.1007/BF02991581. Cell Biophys. 1989. PMID: 2476229
-
MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.Cancer Res. 2007 Dec 15;67(24):11576-84. doi: 10.1158/0008-5472.CAN-07-2756. Cancer Res. 2007. PMID: 18089786 Free PMC article.
-
Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.PLoS One. 2014 Apr 1;9(4):e93404. doi: 10.1371/journal.pone.0093404. eCollection 2014. PLoS One. 2014. PMID: 24690917 Free PMC article.
-
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.Cancer Chemother Pharmacol. 1995;36(6):483-92. doi: 10.1007/BF00685798. Cancer Chemother Pharmacol. 1995. PMID: 7554040
-
Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.Cancer Biol Ther. 2010 Sep 1;10(5):483-91. doi: 10.4161/cbt.10.5.12584. Epub 2010 Sep 4. Cancer Biol Ther. 2010. PMID: 20592495 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical